trial
as of 2026-07-01A Study to Test if TV-46000 is Safe for Maintenance Treatment of Schizophrenia
NCTId NCT03893825
at a glance
Phase 3 · Completed
Enrollment 336 (actual)
Sponsored by Teva Branded Pharmaceutical Products R&D, Inc.
Primary completion 2021-12-02
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 3
Status
Completed
Enrollment
336 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2019-04-17
Primary completion
2021-12-02
Eligibility
ALL · 13 Years · 65 Years
Interventions & indications
Drugs
Indications
Sponsors
Teva Branded Pharmaceutical Products R&D, Inc.Lead Sponsor
Investigators
1
Teva Medical Expert, MDStudy Director
Sites
90 total
Phoenix, United StatesScottsdale, United StatesTucson, United StatesRogers, United StatesAnaheim, United StatesBellflower, United StatesColton, United StatesCosta Mesa, United StatesCulver City, United StatesGlendale, United StatesLa Habra, United StatesLemon Grove, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
336
Phase
PHASE3
Primary Completion Date
2021-12-02
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
indication
indication
indication
investigator
person